Curcumin encapsulated pH sensitive gelatin based interpenetrating polymeric network nanogels for anti cancer drug delivery

Rao, Kummara Madhusudana; Rao, K.S.V. Krishna; Ramanjaneyulu, G.; Ha, Chang‐Sik

doi:10.1016/j.ijpharm.2014.12.001

Cited by 105 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6, P < 0.05). These results agree with the previously reported enhanced therapeutic effect for encapsulated drugs explained by the improved bioavailability of hydrophobic drugs through solubilizing by and non-specific cellular internalization of drug carriers [77,78]. Similarly, in this work, the enhanced BA-TPQ anticancer activity is due to the relatively high hydrophilicity of BA-TPQ-hydrogels unlike BA-TPQ and due to the carrier-assisted transportation of hydrophobic drug across the cell membrane.…”

Section: Resultssupporting

confidence: 93%

Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes

et al. 2017

View full text Add to dashboard Cite

We report a novel delivery platform for a highly potent anticancer drug, 7-(benzylamino)-3,4-dihydro-pyrrolo[4,3,2-de]quinolin-8(1H)-one (BA-TPQ), using pH- and redox-sensitive poly(methacrylic acid) (PMAA) hydrogel cubes of micrometer size as the encapsulating matrix. The hydrogels are obtained upon cross-linking PMAA with cystamine in PMAA/poly(N-vinylpyrrolidone) multilayers assembled within mesoporous sacrificial templates. The BA-TPQ-loaded hydrogels maintain their cubical shape and pH-sensitivity after lyophilization, which is advantageous for long-term storage. Conversely, the particles degrade in vitro in the presence of glutathione (5 mM) providing 80% drug release within 24 h. Encapsulating BA-TPQ into hydrogels significantly increases its transport via Caco-2 cell monolayers used as a model for oral delivery where the apparent permeability of BA-TPQ-hydrogel cubes was ~2-fold higher than that of BA-TPQ. BA-TPQ-hydrogel cubes exhibit better anticancer activity against HepG2 (IC50=0.52 μg/mL) and Huh7 (IC50=0.29 μg/mL) hepatoma cells with a 40% decrease in the IC50 compared to the non-encapsulated drug. Remarkably, non-malignant liver cells have a lower sensitivity to BA-TPQ-hydrogel cubes with 2-fold increased IC50 values compared to those of cancer cells. In addition, encapsulating BA-TPQ in the hydrogels amplifies the potency of the drug via down-regulation of MDM2 oncogenic protein and upregulation of p53 (a tumor suppressor) and p21 (cell proliferation suppressor) expression in HepG2 liver cancer cells. Moreover, enhanced inhibition of MDM2 protein expression by BA-TPQ-hydrogel cubes is independent of p53-status in Huh7 cells. This drug delivery platform of non-spherical shape provides a facile method for encapsulation of hydrophobic drugs and can facilitate the enhanced efficacy of BA-TPQ for liver cancer therapy.

show abstract

Section: Resultssupporting

confidence: 93%

Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In order to overcome the poor absorption, rapid metabolism, and poor bioavailability of curcumin, various pharmaceutical approaches have been developed. These include formulations with nanoparticles (Basniwal et al ., ; Yallapu et al ., ; Yallapu et al ., ), liposomes (Chen et al ., ; Liu et al ., ; Ranjan et al ., ), micelles (Kocher et al ., ; Li et al ., ; Schiborr et al ., ; Wang et al ., ), or interaction with macromolecules such as gelatin (Madhusudana Rao et al ., ) and polysaccharides as galactomannans (Da‐Lozzo et al ., ) and cyclodextrin (Dhule et al ., ; Mangolim et al ., ; Yallapu et al ., ). In addition, curcumin formulations involving hyaluronate vesicles and liposomes (Catalan‐Latorre et al ., ; Manca et al ., ) as well as polymer glycerosomes (Manca et al ., ) have been developed and studied.…”

Section: Introductionmentioning

confidence: 99%

Comparative Oral Absorption of Curcumin in a Natural Turmeric Matrix with Two Other Curcumin Formulations: An Open‐label Parallel‐arm Study

Gopi

Jacob

Varma

et al. 2017

Phytotherapy Research

View full text Add to dashboard Cite

Curcuminoids are the major bioactive molecules in turmeric, and poor bioavailability deters them from being the major components of many health and wellness applications. This study was conducted to assess the bioavailability of a completely natural turmeric matrix formulation (CNTMF) and compare its bioavailability with two other commercially available formulations, namely, curcumin with volatile oil (volatile oil formulation) and curcumin with phospholipids and cellulose (phospholipid formulation) in healthy human adult male subjects (15 each group) under fasting conditions. Each formulation was administrated orally as a single 500-mg dose in capsule form, and blood samples were analyzed by liquid chromatography mass spectrometry at various time intervals up to 24 h. The ingestion of the CNTMF was very well absorbed and resulted in a mean curcuminoids plasma C of 170.14 ng/mL (T = 4 h) compared with 47.54 ng/mL and 69.63 ng/mL for the volatile oil (T = 3 h) and phospholipid (T = 2.25 h) formulations, respectively. The extent of absorption of total curcuminoids in the blood for the CNTMF was 6× greater than volatile oil formulation and 5× greater than phospholipids formulation. The results of this study indicate that curcumin in a natural turmeric matrix exhibited greater bioavailability than the two comparator products. Copyright © 2017 John Wiley & Sons, Ltd.

show abstract

“…Polyacid‐based hydrogels have been widely used for oral drug delivery as they can protect the drugs from proteolytic degradation in the stomach and deliver the drugs to the intestine within a neutral environment . Poly(acrylamidoglycolic acid) (PAGA), an important acrylamide‐based polymer, has been extensively utilized in biomedical applications due to its biocompatibility and ability to remove toxic metal ions . For example, Han and co‐workers fabricated cellulose nanocrystals (CNCs)‐reinforced poly(acrylamidoglycolic acid) (PAGA‐NC) for pH‐sensitive controlled release of diclofenac sodium (DCF) .…”

Section: Autonomous Drug Release Based On Symptom‐associated Signalsmentioning

confidence: 99%

Autonomous Drug Release Systems with Disease Symptom‐Associated Triggers

Xiong

Niu

et al. 2020

Advanced Intelligent Systems

View full text Add to dashboard Cite

Many biophysical and biochemical properties of pathogenic tissues are different from those of healthy tissues. These disease symptom‐associated properties include pH, reduction–oxidation conditions, enzyme generation and expression, blood glucose concentration, mechanical stiffness and strain, and temperature. Autonomous drug release that uses one or more of these disease symptom‐associated properties as the release trigger minimizes the delay in treatments and allows for the release of medications with precisely controlled amounts and with desired spatiotemporal patterns. Herein, a comprehensive assessment of current research progress on autonomous drug release systems (ADRS) is provided. The representative symptoms‐associated properties that can be potentially used as the endogenous stimuli are introduced. The autonomous drug systems that utilize these symptom‐associated signals as the endogenous stimulation signals are discussed, followed by the discussion of current challenges and opportunities in this field, as well as possible future directions in ADRS.

show abstract

Curcumin encapsulated pH sensitive gelatin based interpenetrating polymeric network nanogels for anti cancer drug delivery

Cited by 105 publications

References 26 publications

Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes

Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes

Comparative Oral Absorption of Curcumin in a Natural Turmeric Matrix with Two Other Curcumin Formulations: An Open‐label Parallel‐arm Study

Autonomous Drug Release Systems with Disease Symptom‐Associated Triggers

Contact Info

Product

Resources

About